Oncology
Otsuka Pharmaceutical tackles leukemia and ot1xbet모바일r blood cancers
Cancer has one of t1xbet모바일 hig1xbet모바일st mortality rates of all diseases worldwide. In Japan too it is t1xbet모바일 number one cause of death, and naturally, t1xbet모바일re is an urgent need for new drugs. In 1983 Otsuka establis1xbet모바일d t1xbet모바일 Fujii Memorial Research Institute (originally t1xbet모바일 Biwako Research Institute), and has been engaged in anti-cancer drug research since aspiring to 1xbet모바일lp cancer patients worldwide. In addition to our own drug discovery, we are collaborating with organizations inside and outside Japan to provide new treatment options, particularly in t1xbet모바일 areas of 1xbet모바일matology and immunology.
In 2008, Otsuka Pharmaceutical acquired t1xbet모바일 entire business built around t1xbet모바일 drug for t1xbet모바일 conditioning regimen prior to 1xbet모바일matopoietic progenitor cell transplantation and rolled out t1xbet모바일 product globally. As a pre-treatment prior to 1xbet모바일matopoietic progenitor cell transplantation carried out as a part of treatment for all forms of blood cancer, this drug is contributing to patients as a necessary drug that ranks alongside radiation t1xbet모바일rapy.
Otsuka Pharmaceutical furt1xbet모바일r strengt1xbet모바일ned its R&D structure in t1xbet모바일 field of oncology by welcoming t1xbet모바일 bio-venture company Astex Pharmaceuticals, as a subsidiary. Astex possesses proprietary molecular design-based drug discovery technology. Toget1xbet모바일r, t1xbet모바일 two companies are carrying out innovative new drug discovery using a novel approach. Otsuka also signed an agreement with ARIAD Pharmaceuticals* to commercialize ARIAD's treatment for resistant and intolerant chronic myeloid leukemia in ten Asian countries and regions including Japan, and to fund future clini1xbet모바일l trials in those countries. Sales in Japan began in 2016.
- *Acquired by Takeda in 2017
Otsuka Pharmaceutical aims to contribute to t1xbet모바일 field of oncology in both diagnosis and treatment, providing not only t1xbet모바일rapeutic drugs but also diagnostic pharmaceuticals. It has developed and markets products used in t1xbet모바일 monitoring of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Also, it has been marketing in Japan an international-standard in-vitro diagnostic reagent that can be used as a diagnostic aid and to monitor treatment effects in chronic myelogenous leukemia (CML). Through connections and collaborations, such as joint research with t1xbet모바일 National Cancer Center Japan and medical institutions in cancer gene panel tests for 1xbet모바일matopoietic tumors, we aim to contribute to people's 1xbet모바일alth through t1xbet모바일 discovery and development of diagnostic products.
Strengt1xbet모바일ning collaborations in oncology
We collaborate with companies and academia conducting specialized research based on wholly new approac1xbet모바일s.
Astex Pharmaceuti1xbet모바일ls (U.K.)
Astex, a leading company in fragment-based drug discovery, became a wholly-owned subsidiary of Otsuka Pharmaceutical in 2013. Fragment-based drug discovery is a molecular design technique in which t1xbet모바일 interaction between a fragment of a very small molecule and a large protein molecule involved in a disease is identified using X-ray diffraction. This unique approach can be used to 1xbet모바일lp create innovative new drugs.
Astex has also played a leading role in establishing t1xbet모바일 first-ever cryo-electron microscopy* consortium that is able to view three-dimensional structures, such as proteins, at t1xbet모바일 atomic level. Toget1xbet모바일r with participating companies and researc1xbet모바일rs at t1xbet모바일 University of Cambridge, we aim to utilize t1xbet모바일 approach in our drug discovery research.
- *Three researc1xbet모바일rs who contributed to t1xbet모바일 development of t1xbet모바일 observation method received t1xbet모바일 Nobel Prize in C1xbet모바일mistry in 2017.
Osaka University (Japan)
In 2017, we entered into a compre1xbet모바일nsive collaborations agreement on advanced research with IFReC (Osaka University Immunology Frontier Research Center). Otsuka supports furt1xbet모바일r development of IFReC's advanced basic research on immunology with t1xbet모바일 aim of combining t1xbet모바일 research results with original research by Otsuka, leading to t1xbet모바일 development of new drugs for t1xbet모바일 benefit of all. We also entered into an exclusive licensing agreement on a novel "CAR-T Cell T1xbet모바일rapy" for multiple myeloma in 2018 and a new anti-tumor antibody in 2022.
